[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging in Patients With Progressive Prostate Cancer

What this Trial Is About

This research aims to evaluate the use of PET scans with two different radiotracers, FDG and FDHT, in men with progressive prostate cancer. The study focuses on whether these scans can better detect areas where the cancer may have spread in the body. It builds on earlier findings that changes in FDG uptake relate to cancer progression and treatment response, and now investigates FDHT, which targets the androgen receptor in prostate cancer. Participants will undergo PET scans using FDHT alone or both FDG and FDHT based on clinical questions. Scans will take place at baseline, 4 weeks, 12 weeks, and then every 12 weeks for up to one year, with a maximum of 8 scan sets per year and 40 over a lifetime unless otherwise directed. Some patients may have blood draws to study how FDHT moves through the body and may have an initial dynamic scan followed by a standard whole-body PET scan. During the study, researchers will assess where and how much FDHT accumulates in tumors, comparing these findings with other imaging like bone scans, CT, and MRI at baseline, 4 weeks, and 12 weeks. They will also monitor kinetics and metabolism of the tracer, changes over time, and correlations with disease markers and tissue analyses. The study involves repeated imaging and blood tests to better understand prostate cancer progression and response to treatment.

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer